Online inquiry

IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10268MR)

This product GTTS-WQ10268MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Choroiditis, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10268MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2590MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ1081MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ10713MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ8166MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ5093MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ14970MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ8276MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ12048MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MNRP1685A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW